Showing 7101-7110 of 10172 results for "".
- Cynosure Announces Successful Settlement of Patent Infringement Lawsuitshttps://practicaldermatology.com/news/20131217-cynosure_announces_successful_settlement_of_patent_infringement_lawsuits/2459393/Cynosure, Inc. will receive $10 million plus future royalty payments under a comprehensive settlement agreement with Tria Beauty, Inc. that ends the patent infringement litigation between Tria and Palomar Medical Technologies, which
- FDA Clears Scar Management Gel from Oculus and Quinnovahttps://practicaldermatology.com/news/20131204-fda_clears_scar_management_gel_from_oculus_and_quinnova/2459398/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for Microcyn Scar Management HydroGel, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures, and trauma wounds. Oculus U.S. dermatology partner, Quinnova
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V
- LEO Pharma Expands QualityCareTM Patient Support Programhttps://practicaldermatology.com/news/20131126-leo_pharma_expands_qualitycaretm_patient_support_program/2459403/LEO Pharma Inc. has expanded its QualityCareTM Program, a free and confidential patient support service for people affected by psoriasis or actinic keratosis. In addition to live nurse support through the www.qualitycarebyleo.com, the website also allows patients to choose relevant topics of interes
- KLOX Technologies Announces European CE Mark Approval for Non-Invasive Acne Vulgaris Producthttps://practicaldermatology.com/news/20131119-klox_technologies_announces_european_ce_mark_approval_for_non-invasive_acne_vulgaris_product/2459411/KLOX Technologies Inc. announced that it has received CE mark approval in Europe for its topical photo-converter gel as a Class IIa Medical Device for the treatment of acne vulgaris, including all severities. The gel is part of the company's LumiCleanse System, a first-in-class,
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Data Indicate Need to Critically Assess Sunscreen Formulationshttps://practicaldermatology.com/news/20131107-data_indicate_need_to_critically_assess_sunscreen_formulations/2459419/When it comes to sunscreen selection, consumers may benefit from an assessment of a product's specific formulation rather than simply a “Broad Spectrum” claim, according to a poster presented at last month's Fall Clinical Dermatology Conference (Ouyang, et al.). The poster analyzed the critical wave
- Cosmetic Surgery Forum Announces Innovators in Dermatology Recipientshttps://practicaldermatology.com/news/20131107-cosmetic_surgery_forum_announces_innovators_in_dermatology_recipients/2459420/The upcoming Cosmetic Surgery Forum (www.cosmeticsurgeryforum.com), taking place at the ARIA Resort and Casino in Las Vegas from December 5-7, recently announced the recipients of its “Innovators in Dermatology” presentation. Among those honored this year will be Jim Hartman, Vice President of US Ae
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo